2017
DOI: 10.1177/2050313x17692936
|View full text |Cite
|
Sign up to set email alerts
|

Switching to aripiprazole for the treatment of residual mutism resulted in distinct clinical courses in two catatonic schizophrenia cases

Abstract: Objectives:The efficacy of a partial agonist for the dopamine D2 receptor, aripiprazole, for catatonia in schizophrenia has been reported.Methods:We report distinct clinical courses in challenging aripiprazole to treat residual mutism after severe catatonic symptoms improved.Results:In the first case, mutism was successfully treated when the patient was switched from olanzapine to aripiprazole. In contract, switching to aripiprazole from risperidone aggravated auditory hallucinations in the second case.Conclus… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
2
0
1

Year Published

2017
2017
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(3 citation statements)
references
References 14 publications
0
2
0
1
Order By: Relevance
“…Due to its lower affinity to the D 2 -receptor, aripiprazole may not control positive symptoms of schizophrenia as well as other antipsychotic medications. Cases have been reported where auditory hallucinations developed after a patient with schizophrenia was switched from another antipsychotic medication (risperidone) to aripiprazole to treat mutism, and aripiprazole had to be discontinued [18].…”
Section: Discussionmentioning
confidence: 99%
“…Due to its lower affinity to the D 2 -receptor, aripiprazole may not control positive symptoms of schizophrenia as well as other antipsychotic medications. Cases have been reported where auditory hallucinations developed after a patient with schizophrenia was switched from another antipsychotic medication (risperidone) to aripiprazole to treat mutism, and aripiprazole had to be discontinued [18].…”
Section: Discussionmentioning
confidence: 99%
“…В ряду перспективных методов фармакологической коррекции кататонии при шизофрении могут рассматриваться антипсихотики так называемого третьего поколения (АТП), сочетающие высокий аффинитет к дофаминовым рецепторам с механизмом парциального D2/D3 агонизма. Ранее были получены положительные результаты применения в терапии кататонии при шизофрении арипипразола, первого АТП со свойствами парциального агониста D2-рецепторов [77]. В приведенном исследовании на основании двух клинических случаев пациентов с кататонической шизофренией авторы изучали влияние арипипразола на остаточные после перенесенного кататонического приступа проявления мутизма.…”
Section: нейролептические препараты (антипсихотики)unclassified
“…Several reports suggest a beneficial effect of clozapine and second-generation antipsychotics (SGAs) in the treatment of (chronic) schizophrenic catatonia. SGA with low D2 blockade (quetiapine, olanzapine, clozapine) (Tabbane et al, 2016) or with D2 partial agonism (aripiprazole) (Muneoka et al, 2017) should be favored, and can, of course, be used to treat residual psychotic symptomatology or as a prophylactic treatment in psychotic disorders and mood disorders (Sienaert et al, 2014).…”
Section: Antipsychoticsmentioning
confidence: 99%